Evaluation of serum M30 and M65 activity in patients with stage-I endometrial cancer

References

• Arends MJ. 1999. Apoptosis in the endometrium. Histopathology 35:174–178.
   PubMed Web of Science ®Google Scholar
• Arioz DT, Camuzcuoglu H, Toy H, Kurt S, Celik H, Aksoy N. 2009. Serum prolidase activity and oxidative status in patients with stage I endometrial cancer. International Journal of Gynecological Cancer 19:1244–1247.
   PubMed Web of Science ®Google Scholar
• Bilici A, Ustaalioglu BBO, Ercan S, Orcun A, Seker M, Salepci T, et al. 2011. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer? Cancer Chemotherapy and Pharmacology 68:309–316.
   PubMed Web of Science ®Google Scholar
• Boll D, Karim-Kos HE, Verhoeven RHA, Burger CW, Coebergh JW, van de Poll-Franse LV, et al. 2013. Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in The Netherlands: a population based study. European Journal of Obstetrics and Gynecology and Reproductive Biology 166:209–214.
   PubMed Web of Science ®Google Scholar
• Carlson JW, Mutter GL. 2008. Endometrial intraepithelial neoplasia is associated with polyps and frequently has metaplastic change. Histopathology 53:325–332.
   PubMed Web of Science ®Google Scholar
• Chan QKY, Ngan HYS, Ip PPC, Liu VWS, Xue WC, Cheung ANY. 2009. Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis. Carcinogenesis 30:114–121.
   PubMed Web of Science ®Google Scholar
• Chiu PM, Ngan YS, Khoo US, Cheung AN. 2001. Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology 38:243–249.
   PubMed Web of Science ®Google Scholar
• Ellis RE, Yuan JY, Horvitz HR. 1991. Mechanisms and functions of cell death. Annual Review of Cell Biology 7:663–698.
   PubMed Web of Science ®Google Scholar
• Faul F, Erdfelder E, Lang A-G, Buchner A. 2007. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 39:175–191.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Koukourakis MI, Harris AL, Gatter KC. 1998. Bcl-2 and p53 expression in stage I endometrial carcinoma. Anticancer Research 18:3689–3693.
   PubMed Web of Science ®Google Scholar
• Incebiyik A, Camuzcuoglu H, Vural M, Hilali NG, Camuzcuoglu A, Seker A, et al. 2016. Assessment of apoptotic activity dysregulation and oxidative stress in the development of epithelial ovarian cancer: a case-controlled descriptive analysis. Gynecologic and Obstetric Investigation 81:71–77.
   PubMed Web of Science ®Google Scholar
• Incebiyik A, Vural M, Camuzcuoglu H, Taskin A, Camuzcuoglu A, Hilali NG, et al. 2016. Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole? Wiener Klinische Wochenschrift 128:566–571.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA: A Cancer Journal for Clinicians 61:69–90.
   PubMed Web of Science ®Google Scholar
• Morsi HM, Leers MPG, Jager W, Bjorklund V, Radespiel-Troger M, Kabarity HE, et al. 2000. The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic, and malignant endometrium. International Journal of Gynecologic Pathology 19:118–126.
   PubMed Web of Science ®Google Scholar
• Morsi HM, Leers MPG, Radespiel-Tröger M, Björklund V, Kabarity H, El Nap M, et al. 2000. Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: an approach using multiparameter flow cytometry. Gynecologic Oncology 77:11–17.
   PubMed Web of Science ®Google Scholar
• Oven Ustaalioglu B, Bilici A, Ercan S, Orcun A, Seker M, Ozkan A, et al. 2012. Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls. Clinical and Translational Oncology 14:356–361.
   PubMed Web of Science ®Google Scholar
• Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. 2009. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. International Immunopharmacology 9:645–648.
   PubMed Web of Science ®Google Scholar
• Saitoh Y, Yaginuma Y, Ishikawa M. 1999. Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. International Journal of Oncology 15:137–141.
   PubMed Web of Science ®Google Scholar
• Sharp AN, Heazell AEP, Crocker IP, Mor G. 2010. Placental apoptosis in health and disease. American Journal of Reproductive Immunology (New York, N.Y. : 1989) 64:159–169.
   PubMed Web of Science ®Google Scholar
• Sorosky JI. 2008. Endometrial cancer. Obstetrics and Gynecology 111:436–447.
   PubMed Web of Science ®Google Scholar
• Stewart CJ, Campbell-Brown M, Critchley HO, Farquharson MA. 1999. Endometrial apoptosis in patients with dysfunctional uterine bleeding. Histopathology 34:99–105.
   PubMed Web of Science ®Google Scholar
• Thompson CB. 1995. Apoptosis in the pathogenesis and treatment of disease. Science (New York, N.Y.) 267:1456–1462.
   PubMed Web of Science ®Google Scholar
• Ueno T, Toi M, Linder S. 2005. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomedicine and Pharmacotherapy = Biomedecine and Pharmacotherapie 59 Suppl 2:S359–S362.
   PubMedGoogle Scholar
• Ustaalioglu BBO, Bilici A, Ercan S, Seker M, Orcun A, Gumus M. 2013. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer. Medical Oncology 30:551.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang J, Wang H, Yang X. 2003. Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis. Zhonghua Bing li Xue za Zhi = Chinese Journal of Pathology 32:314–318.
   PubMedGoogle Scholar
• Yildiz I, Sen F, Kilic L, Keskin S, Duranyildiz D, Bilgin E, et al. 2013. Serum M65 as a biomarker for metastatic renal cell carcinoma. Clinical Genitourinary Cancer 11:290–296.
   PubMed Web of Science ®Google Scholar
• Yildiz I, Tas F, Kilic L, Sen F, Saip P, Eralp Y, et al. 2013. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology 72:437–444.
   PubMed Web of Science ®Google Scholar